Tobira Therapeutics Inc. (NASDAQ:TBRA) major shareholder Pentwater Capital Management L bought 1,624,200 shares of the company’s stock in a transaction on Thursday, September 22nd. The shares were acquired at an average cost of $39.04 per share, for a total transaction of $63,408,768.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Pentwater Capital Management L also recently made the following trade(s):
- On Friday, September 23rd, Pentwater Capital Management L bought 100,000 shares of Tobira Therapeutics stock. The shares were acquired at an average cost of $39.19 per share, for a total transaction of $3,919,000.00.
Tobira Therapeutics Inc. (NASDAQ:TBRA) opened at 38.99 on Tuesday. The stock’s 50 day moving average is $9.62 and its 200 day moving average is $9.17. Tobira Therapeutics Inc. has a 52-week low of $3.76 and a 52-week high of $41.39. The company’s market cap is $733.83 million.
Tobira Therapeutics (NASDAQ:TBRA) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.08. The firm had revenue of $1.06 million for the quarter. On average, analysts predict that Tobira Therapeutics Inc. will post ($2.65) earnings per share for the current fiscal year.
TBRA has been the topic of a number of research reports. Cantor Fitzgerald cut shares of Tobira Therapeutics to a “buy” rating and set a $19.00 target price on the stock. in a report on Monday, July 25th. Zacks Investment Research raised shares of Tobira Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Wednesday, July 13th. HC Wainwright reissued a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, June 28th. Cowen and Company restated a “buy” rating and set a $11.00 price target on shares of Tobira Therapeutics in a research report on Wednesday, August 10th. Finally, Mizuho restated a “buy” rating and set a $305.00 price target on shares of Tobira Therapeutics in a research report on Thursday, September 22nd. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $68.63.
Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Tobira Therapeutics by 2.5% in the first quarter. Geode Capital Management LLC now owns 32,223 shares of the biopharmaceutical company’s stock valued at $263,000 after buying an additional 799 shares during the last quarter. Franklin Resources Inc. bought a new stake in shares of Tobira Therapeutics during the first quarter valued at about $4,797,000. State Street Corp increased its stake in shares of Tobira Therapeutics by 184.3% in the first quarter. State Street Corp now owns 42,875 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 27,794 shares during the last quarter. Teachers Advisors Inc. increased its stake in shares of Tobira Therapeutics by 287.1% in the second quarter. Teachers Advisors Inc. now owns 14,484 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 10,742 shares during the last quarter. Finally, TFS Capital LLC bought a new stake in shares of Tobira Therapeutics during the second quarter valued at about $533,000. Institutional investors and hedge funds own 62.02% of the company’s stock.
About Tobira Therapeutics
Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.
Receive News & Ratings for Tobira Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.